16:28 EST Sangamo (SGMO) down 31% at $1.61 after Pfizer decision to terminate collaboration
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
- Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer
- Sangamo to receive $20M from Astellas Pharma in capsid license agreement
- Biotech Alert: Searches spiking for these stocks today
- Sangamo upgraded to Buy from Hold at Truist
- Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success